VivoSense announces an expansion of our collaboration with the Rett Syndrome Research Trust (RSRT). Building on the success of our previous collaborations, VivoSense and RSRT will continue to support the development of treatments for Rett Syndrome (RTT) by qualifying objective digital outcome measures of breathing problems for use in RTT trials.
RTT patient data gathered from wearable sensors is an invaluable resource for better understanding the impact of symptoms on the daily lives of patients and for assessing the effectiveness of new treatments. This multi-phase project aims to provide scientific rationale, establish feasibility and usability, and develop and validate the proposed digital clinical outcome measures, culminating in an application for a qualified clinical outcome assessment with the FDA.
For the nearly 30 million Americans living with rare diseases, research into new therapies is essential. A growing interest in the development of new drug and therapeutic approaches for rare diseases, such as RTT, fueled by recent scientific advances, offers hope to these patients. With several drug candidates reaching open-label and gene therapy on the horizon, we are committed to doing our part. Qualified clinical outcomes will speed the evaluation and potentially the adoption of new therapies for RTT.
As part of our ongoing collaboration with RSRT, we hope to continue improving treatments and outcomes for patients living with RTT through the development and qualification of novel biomarkers.
About VivoSense
VivoSense, Inc., is an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data. We are focused on healthcare clinical trial research & care. VivoSense’s hypothesis-driven framework provides analytical and clinical validation leading to FDA approval. The proprietary VivoSense® software enables the creation and validation of novel digital biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials.
For more information about how rare disease researchers can use wearable sensors to develop digital clinical measures to improve patient outcomes, check out the article and video: Example of Novel Respiratory Endpoint Discovery Using Real-World Data.
About Rett Syndrome Research Trust
RSRT is a nonprofit organization with a highly personal and urgent mission: achieving a cure for Rett syndrome and related disorders caused by defects in the MECP2 gene. Since its founding in 2008, RSRT has awarded $66 million, more than any other Rett organization in the world, to leading scientists pursuing targeted research on Rett. RSRT funds and spearheads global scientific and clinical activities advancing the most promising curative approaches. To date, every biopharmaceutical company pursuing a cure for Rett syndrome is doing so because they leveraged discoveries and resources incubated with RSRT funding.
To learn more, please visit www.reverserett.org.
Dudley Tabakin
Dudley Tabakin, MSc. is Chief Product Officer and co-founder of VivoSense and a fervent believer in “good data” over “big data” in the development of digital endpoints from wearable sensor technology.
LinkedIn Profile for VivoSense Announces Expanded Collaboration with RSRT